Litcius/Paper detail

HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population

Pei Zeng, Xiangsheng Cai, Xiaozhou Yu, Lu Huang, Xi Chen

2023Journal of International Medical Research22 citationsDOIOpen Access PDF

Abstract

OBJECTIVES: This study aimed to investigate the correlation between homeostasis model assessment of insulin resistance (HOMA-IR) and non-alcoholic fatty liver disease (NAFLD) in the non-diabetic population and establish its diagnostic efficacy. METHODS: This observational study involved participants divided into NAFLD and non-NAFLD groups, and baseline data were analyzed. Univariate and multivariate logistic regression analyses were used to correlate HOMA-IR with the risk of NAFLD. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of HOMA-IR for NAFLD. Subgroup analyses of non-obese individuals were performed. RESULTS: Overall, 2234 non-diabetic participants were included. The HOMA-IR was significantly higher in the NAFLD group than in the non-NAFLD group. Multivariate logistic regression analysis showed that HOMA-IR was a strong and independent risk factor for NAFLD after correcting for confounding factors. The area under the ROC curve (AUC) value of HOMA-IR for predicting NAFLD was 0.792. In the non-obese non-diabetic population, HOMA-IR was an independent risk factor for increased risk of lean NAFLD after correcting for confounding factors. The AUC value of HOMA-IR for predicting lean NAFLD was 0.770. CONCLUSIONS: HOMA-IR is independently associated with the risk of NAFLD in the non-diabetic and non-obese non-diabetic populations and has good diagnostic value.

Topics & Concepts

MedicineInternal medicineFatty liverConfoundingInsulin resistanceGastroenterologyPopulationDiabetes mellitusRisk factorLogistic regressionBiomarkerReceiver operating characteristicDiseaseEndocrinologyObesityBiologyBiochemistryEnvironmental healthLiver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases